亚胺培南联合利奈唑胺治疗对吸入性肺炎患者血清ANXA1、IRF5和HBP水平的影响

Effects of Imipenem Combined with Linezolid on Serum ANXA1, IRF5, and HBP Levels in Patients with Aspiration Pneumonia

摘要

目的 探讨亚胺培南联合利奈唑胺治疗对吸入性肺炎患者血清膜联蛋白A1（annexin A1，ANXA1）、干扰素调节因子5（interferon regulatory factor 5，IRF5）和肝素结合蛋白（heparin binding protein，HBP）水平的影响。方法 回顾性分析衡水市第二人民医院于2023年3月至2025年3月收治的270例吸入性肺炎患者的资料，依据患者用药方案分为对照组（n = 135）与观察组（n = 135）。对照组静脉滴注亚胺培南，观察组在对照组基础上增加静脉滴注利奈唑胺，均持续14 d。比较2组的疗效、白细胞（white blood cell，WBC）计数、降钙素原（procalcitonin，PCT）、C反应蛋白（C-reactive protein，CRP）、白介素-6（interleukin-6，IL-6）和肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）、ANXA1、IRF5和HBP水平以及不良反应。经Pearson相关性分析ANXA1、IRF5和HBP与WBC、PCT、CRP、IL-6及TNF-α的相关性。结果 观察组的总有效率高于对照组（P ＜ 0.05）。2组治疗7、14 d的WBC、PCT、CRP、IL-6、TNF-α、IRF5和HBP水平低于治疗前，ANXA1水平高于治疗前（P ＜ 0.05），且2组治疗14 d的上述指标水平优于治疗7 d（P ＜ 0.05）；观察组治疗7、14 d的WBC、PCT、CRP、IL-6、TNF-α、IRF5和HBP水平低于对照组，ANXA1水平高于对照组（P ＜ 0.05）。2组不良反应经比较，差异无统计学意义（P ＞ 0.05）。经Pearson相关性分析，ANXA1与WBC、PCT、CRP、IL-6、TNF-α呈负相关，而IRF5和HBP与WBC、PCT、CRP、IL-6和TNF-α呈正相关（P ＜ 0.05）。结论 亚胺培南联合利奈唑胺治疗吸入性肺炎患者疗效显著，能显著减轻炎症反应，提高ANXA1水平，降低IRF5和HBP水平，且ANXA1、IRF5和HBP与炎症反应密切相关。

Abstract

Objective To investigate the effects of imipenem combined with linezolid on serum levels of annexin A1 (ANXA1), interferon regulatory factor 5 (IRF5), and heparin-binding protein (HBP) in patients with aspiration pneumonia. Methods A retrospective analysis was conducted on 270 patients with aspiration pneumonia admitted to the Second People's Hospital of Hengshui from March 2023 to March 2025. Based on their medication regimens, patients were divided into a control group (n= 135) and an intervention group (n= 135). The control group received intravenous imipenem, while the intervention group received intravenous infusion of linezolid in addition to the imipenem regimen. Both groups were treated for 14 days. The two groups were compared in terms of therapeutic efficacy, white blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), ANXA1, IRF5, and HBP levels, as well as adverse reactions. Pearson correlation analysis was used to assess the correlations of ANXA1, IRF5, and HBP with WBC, PCT, CRP, IL-6, and TNF-α. Results The total effective rate in the intervention group was significantly higher than that in the control group (P＜ 0.05). After 7 and 14 days of treatment, the levels of WBC, PCT, CRP, IL-6, TNF-α, IRF5, and HBP in both groups were significantly lower than those before treatment, while ANXA1 levels were significantly higher (P＜ 0.05). Furthermore, the levels of these indicators at 14 days of treatment were superior to those at 7 days in both groups (P＜ 0.05). At both 7 and 14 days of treatment, the intervention group showed significantly lower levels of WBC, PCT, CRP, IL-6, TNF-α, IRF5, and HBP, and significantly higher ANXA1 levels compared to the control group (P＜ 0.05). No statistically significant difference was observed in adverse reactions between the two groups (P＞ 0.05). Pearson correlation analysis revealed that ANXA1 was negatively correlated with WBC, PCT, CRP, IL-6, and TNF-α, whereas IRF5 and HBP were positively correlated with these inflammatory markers (P＜ 0.05). Conclusion The combination of imipenem and linezolid demonstrates significant efficacy in treating patients with aspiration pneumonia, markedly alleviating the inflammatory response, increasing ANXA1 levels, and decreasing IRF5 and HBP levels, and ANXA1, IRF5, and HBP are closely related to the inflammatory response.

关键词

吸入性肺炎 / 亚胺培南 / 利奈唑胺 / 膜联蛋白A1 / 干扰素调节因子5 / 肝素结合蛋白

Key words

aspiration pneumonia / imipenem / linezolid / annexin A1 / interferon regulatory factor 5 / heparin-binding protein

参考文献

[1] Bai A D, Srivastava S, Digby G C,et al. Anaerobic antibiotic coverage in aspiration pneumonia and the associated benefits and harms: a retrospective cohort study[J].Chest, 2024, 166(1): 39-48.

[2] Masuda H, Ueha R, Sato T,et al. Risk factors for aspiration pneumonia after receiving liquid—thickening recommendations[J].Otolaryngol Head Neck Surg, 2022, 167(1): 125-132.

[3] 李缜, 宋建梅, 李晓阳. 吸入性肺炎病原菌分布及其多重耐药菌的危险因素分析[J].标记免疫分析与临床, 2025, 32(2): 262-266.

[4] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志, 2016, 39(4): 253-279.

[5] 陈杰, 彭君琴, 龚秀敏. 感染病原菌、HBP、CHE、suPAR对老年吸入性肺炎患者预后的预测价值[J].中国老年学杂志, 2025, 45(14): 3385-3388.

[6] 张露, 王庆东, 徐正军. 经鼻高流量湿化氧疗联合气管镜吸痰治疗老年吸入性肺炎的临床疗效[J].江苏医药, 2024, 50(9): 925—927, 931.

[7] 鹿中华, 余维丽, 周强, 等. 早期气管镜灌洗在吸入性肺炎患者中的疗效[J].中华急诊医学杂志, 2022, 31(6): 809-816.

[8] 洪丽明, 李乐辉, 田秘, 等. 亚胺培南治疗肺炎克雷伯菌肺部感染的药代动力学及其与临床疗效的关系[J].中华医院感染学杂志, 2021, 31(9): 1343-1347.

[9] 宋林燕, 杨晓帆, 黄正米, 等. 亚胺培南西司他丁联合利奈唑胺治疗老年重症肺炎的研究[J].西北药学杂志, 2023, 38(3): 172-175.

[10] 张怡千, 文惠韬. 利奈唑胺辅助治疗对肺结核合并细菌感染性重症肺炎患者免疫因子及预后的影响[J].中国防痨杂志, 2024, 46(S1): 46-49.

[11] 徐震林, 李奕鑫, 赵国平, 等. 利奈唑胺联合美罗培南对重症肺炎患者血气指标及血清膜联蛋白A1水平的影响[J].疑难病杂志, 2025, 24(3): 318-322.

[12] 赵迎东, 薛晓丽, 孙伯艳, 等. 肺部超声与IRF5和IL—10基因多态性对早产儿肺部感染的诊断价值[J].中华医院感染学杂志, 2024, 34(16): 2500-2504.

[13] 李甲, 郑立慧, 李霞. 血清sTREM—1、8—OHdG、HBP与肺炎严重程度的关系及其在重症肺炎患者中的预后价值[J].转化医学杂志, 2024, 13(6): 889-894.

基金资助

衡水市重点研发计划项目(2022014069Z)